The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2023 | Predicting response to CAR-T therapy in lymphoma: challenges and strategies
Michael Green, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the challenges in predicting patient response to CAR-T therapy, which can be dependent on a variety of factors such as the tumor microenvironment and the patient’s T-cells. Dr Green describes a metric which is currently used and highlights the need for a more holistic model. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Sanofi, Kite/Gilead, Abbvie and Allogene; consulting for Abbvie, Allogene and Bristol Myers Squibb; honoraria from Tessa Therapeutics, Monte Rosa Therapeutics, Daiichi Sankyo and DAVA Oncology; and stock ownership of KDAc Therapeutics
